CN111000237A - 一种用于心脑血管病膳食干预的膳食组合物及制备方法 - Google Patents
一种用于心脑血管病膳食干预的膳食组合物及制备方法 Download PDFInfo
- Publication number
- CN111000237A CN111000237A CN201911354632.7A CN201911354632A CN111000237A CN 111000237 A CN111000237 A CN 111000237A CN 201911354632 A CN201911354632 A CN 201911354632A CN 111000237 A CN111000237 A CN 111000237A
- Authority
- CN
- China
- Prior art keywords
- extract
- powder
- ethanol
- hericium erinaceus
- preparing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 235000007882 dietary composition Nutrition 0.000 title claims abstract description 34
- 208000024172 Cardiovascular disease Diseases 0.000 title claims abstract description 31
- 208000026106 cerebrovascular disease Diseases 0.000 title claims abstract description 28
- 230000002526 effect on cardiovascular system Effects 0.000 title claims abstract description 28
- 238000002360 preparation method Methods 0.000 title claims abstract description 19
- 235000021196 dietary intervention Nutrition 0.000 title claims abstract description 11
- 239000000284 extract Substances 0.000 claims abstract description 148
- 239000000843 powder Substances 0.000 claims abstract description 129
- 240000000588 Hericium erinaceus Species 0.000 claims abstract description 73
- 235000007328 Hericium erinaceus Nutrition 0.000 claims abstract description 73
- 239000000049 pigment Substances 0.000 claims abstract description 58
- 240000001548 Camellia japonica Species 0.000 claims abstract description 47
- 241000007126 Codonopsis pilosula Species 0.000 claims abstract description 41
- 235000020717 hawthorn extract Nutrition 0.000 claims abstract description 36
- 235000019206 astragalus extract Nutrition 0.000 claims abstract description 35
- 235000006467 Camellia japonica Nutrition 0.000 claims abstract description 32
- 241000756943 Codonopsis Species 0.000 claims abstract description 21
- 238000002156 mixing Methods 0.000 claims abstract description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 173
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 90
- 244000269722 Thea sinensis Species 0.000 claims description 86
- 235000013616 tea Nutrition 0.000 claims description 70
- 238000003809 water extraction Methods 0.000 claims description 70
- 239000000243 solution Substances 0.000 claims description 51
- 238000001914 filtration Methods 0.000 claims description 50
- 239000000706 filtrate Substances 0.000 claims description 40
- 238000000605 extraction Methods 0.000 claims description 32
- 239000006228 supernatant Substances 0.000 claims description 25
- 238000000034 method Methods 0.000 claims description 22
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 20
- 239000001963 growth medium Substances 0.000 claims description 20
- 238000009630 liquid culture Methods 0.000 claims description 20
- 239000011259 mixed solution Substances 0.000 claims description 20
- 239000002244 precipitate Substances 0.000 claims description 20
- 238000001694 spray drying Methods 0.000 claims description 20
- 239000011550 stock solution Substances 0.000 claims description 20
- 238000000855 fermentation Methods 0.000 claims description 17
- 230000004151 fermentation Effects 0.000 claims description 17
- 241001061264 Astragalus Species 0.000 claims description 15
- 241001092040 Crataegus Species 0.000 claims description 15
- 235000009917 Crataegus X brevipes Nutrition 0.000 claims description 15
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 claims description 15
- 235000009685 Crataegus X maligna Nutrition 0.000 claims description 15
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 claims description 15
- 235000009486 Crataegus bullatus Nutrition 0.000 claims description 15
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 claims description 15
- 235000009682 Crataegus limnophila Nutrition 0.000 claims description 15
- 235000004423 Crataegus monogyna Nutrition 0.000 claims description 15
- 235000002313 Crataegus paludosa Nutrition 0.000 claims description 15
- 235000009840 Crataegus x incaedua Nutrition 0.000 claims description 15
- 235000006533 astragalus Nutrition 0.000 claims description 15
- 238000009835 boiling Methods 0.000 claims description 15
- 235000018597 common camellia Nutrition 0.000 claims description 15
- 235000009569 green tea Nutrition 0.000 claims description 15
- 210000004233 talus Anatomy 0.000 claims description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 15
- 150000004676 glycans Chemical class 0.000 claims description 14
- 229920001282 polysaccharide Polymers 0.000 claims description 14
- 239000005017 polysaccharide Substances 0.000 claims description 14
- 150000008442 polyphenolic compounds Chemical class 0.000 claims description 11
- 235000013824 polyphenols Nutrition 0.000 claims description 11
- 241001657422 Camellia petelotii Species 0.000 claims description 10
- 108010059892 Cellulase Proteins 0.000 claims description 10
- 108090000790 Enzymes Proteins 0.000 claims description 10
- 102000004190 Enzymes Human genes 0.000 claims description 10
- 229940106157 cellulase Drugs 0.000 claims description 10
- 238000005238 degreasing Methods 0.000 claims description 10
- 238000001035 drying Methods 0.000 claims description 10
- 229940088598 enzyme Drugs 0.000 claims description 10
- 238000001704 evaporation Methods 0.000 claims description 10
- 230000000415 inactivating effect Effects 0.000 claims description 10
- 238000010992 reflux Methods 0.000 claims description 10
- 238000007873 sieving Methods 0.000 claims description 10
- 238000005406 washing Methods 0.000 claims description 10
- 239000009636 Huang Qi Substances 0.000 claims description 9
- 230000008569 process Effects 0.000 claims description 8
- 239000007788 liquid Substances 0.000 claims description 6
- 239000012141 concentrate Substances 0.000 claims description 5
- 238000012258 culturing Methods 0.000 claims description 5
- 238000010438 heat treatment Methods 0.000 claims description 5
- 239000012528 membrane Substances 0.000 claims description 5
- 238000010899 nucleation Methods 0.000 claims description 5
- 230000001376 precipitating effect Effects 0.000 claims description 5
- 235000006468 Thea sinensis Nutrition 0.000 claims description 3
- 229940116746 camellia sinensis flower extract Drugs 0.000 claims 1
- 230000003405 preventing effect Effects 0.000 abstract description 11
- 241001122767 Theaceae Species 0.000 abstract description 3
- 230000003750 conditioning effect Effects 0.000 abstract description 3
- 239000003814 drug Substances 0.000 description 24
- 230000000694 effects Effects 0.000 description 22
- 210000004369 blood Anatomy 0.000 description 20
- 239000008280 blood Substances 0.000 description 20
- 230000001603 reducing effect Effects 0.000 description 14
- 229940079593 drug Drugs 0.000 description 10
- 230000009471 action Effects 0.000 description 9
- 230000036772 blood pressure Effects 0.000 description 9
- 208000007536 Thrombosis Diseases 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 241000196324 Embryophyta Species 0.000 description 7
- 208000031226 Hyperlipidaemia Diseases 0.000 description 7
- 230000017531 blood circulation Effects 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 239000003925 fat Substances 0.000 description 7
- 235000013305 food Nutrition 0.000 description 7
- 210000000952 spleen Anatomy 0.000 description 7
- 241001328788 Camellia nitidissima Species 0.000 description 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
- 230000036541 health Effects 0.000 description 6
- 230000001737 promoting effect Effects 0.000 description 6
- 230000006870 function Effects 0.000 description 5
- 230000036039 immunity Effects 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 150000002632 lipids Chemical class 0.000 description 5
- 230000000144 pharmacologic effect Effects 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 241000123222 Hericium Species 0.000 description 4
- 241000282414 Homo sapiens Species 0.000 description 4
- 206010020772 Hypertension Diseases 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 235000005911 diet Nutrition 0.000 description 4
- 206010067484 Adverse reaction Diseases 0.000 description 3
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- 206010012735 Diarrhoea Diseases 0.000 description 3
- 108050009340 Endothelin Proteins 0.000 description 3
- 102000002045 Endothelin Human genes 0.000 description 3
- 229960001138 acetylsalicylic acid Drugs 0.000 description 3
- 230000006838 adverse reaction Effects 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 235000012000 cholesterol Nutrition 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 230000000378 dietary effect Effects 0.000 description 3
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 3
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 2
- 229930182837 (R)-adrenaline Natural products 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- 208000010201 Exanthema Diseases 0.000 description 2
- 108010049003 Fibrinogen Proteins 0.000 description 2
- 102000008946 Fibrinogen Human genes 0.000 description 2
- 241000628997 Flos Species 0.000 description 2
- 108010023302 HDL Cholesterol Proteins 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 108010028554 LDL Cholesterol Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010028813 Nausea Diseases 0.000 description 2
- 108010025020 Nerve Growth Factor Proteins 0.000 description 2
- 102000015336 Nerve Growth Factor Human genes 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 208000032109 Transient ischaemic attack Diseases 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 2
- 229960000830 captopril Drugs 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 230000015271 coagulation Effects 0.000 description 2
- 238000005345 coagulation Methods 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 229960005139 epinephrine Drugs 0.000 description 2
- 201000005884 exanthem Diseases 0.000 description 2
- 229940012952 fibrinogen Drugs 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 231100000206 health hazard Toxicity 0.000 description 2
- 201000001421 hyperglycemia Diseases 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 230000008693 nausea Effects 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- 206010037844 rash Diseases 0.000 description 2
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 230000035922 thirst Effects 0.000 description 2
- 201000010875 transient cerebral ischemia Diseases 0.000 description 2
- 150000003648 triterpenes Chemical class 0.000 description 2
- FJLGEFLZQAZZCD-MCBHFWOFSA-N (3R,5S)-fluvastatin Chemical compound C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 FJLGEFLZQAZZCD-MCBHFWOFSA-N 0.000 description 1
- DNXIKVLOVZVMQF-UHFFFAOYSA-N (3beta,16beta,17alpha,18beta,20alpha)-17-hydroxy-11-methoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]-yohimban-16-carboxylic acid, methyl ester Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(C(=O)OC)C(O)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 DNXIKVLOVZVMQF-UHFFFAOYSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 239000005541 ACE inhibitor Substances 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 241000222382 Agaricomycotina Species 0.000 description 1
- 201000010000 Agranulocytosis Diseases 0.000 description 1
- 208000028185 Angioedema Diseases 0.000 description 1
- 206010002660 Anoxia Diseases 0.000 description 1
- 241000976983 Anoxia Species 0.000 description 1
- 206010003226 Arteriovenous fistula Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 1
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 description 1
- 206010003658 Atrial Fibrillation Diseases 0.000 description 1
- 235000011299 Brassica oleracea var botrytis Nutrition 0.000 description 1
- 240000003259 Brassica oleracea var. botrytis Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000526900 Camellia oleifera Species 0.000 description 1
- 241000208671 Campanulaceae Species 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 206010008132 Cerebral thrombosis Diseases 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 241000357628 Codonopsis pilosula subsp. tangshen Species 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 235000017159 Crataegus pinnatifida Nutrition 0.000 description 1
- 241000657480 Crataegus pinnatifida Species 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 206010053155 Epigastric discomfort Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 206010018687 Granulocytopenia Diseases 0.000 description 1
- 108010010234 HDL Lipoproteins Proteins 0.000 description 1
- 102000015779 HDL Lipoproteins Human genes 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- 208000006083 Hypokinesia Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 206010061245 Internal injury Diseases 0.000 description 1
- 201000001429 Intracranial Thrombosis Diseases 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- IPMYMEWFZKHGAX-UHFFFAOYSA-N Isotheaflavin Natural products OC1CC2=C(O)C=C(O)C=C2OC1C(C1=C2)=CC(O)=C(O)C1=C(O)C(=O)C=C2C1C(O)CC2=C(O)C=C(O)C=C2O1 IPMYMEWFZKHGAX-UHFFFAOYSA-N 0.000 description 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 1
- 102000007330 LDL Lipoproteins Human genes 0.000 description 1
- 206010024264 Lethargy Diseases 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 210000004460 N cell Anatomy 0.000 description 1
- 208000000592 Nasal Polyps Diseases 0.000 description 1
- 206010028748 Nasal obstruction Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000025047 Non-histaminic angioedema Diseases 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 102000015795 Platelet Membrane Glycoproteins Human genes 0.000 description 1
- 108010010336 Platelet Membrane Glycoproteins Proteins 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 208000008425 Protein deficiency Diseases 0.000 description 1
- 108010094028 Prothrombin Proteins 0.000 description 1
- 102100027378 Prothrombin Human genes 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010038084 Rectocele Diseases 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- LCQMZZCPPSWADO-UHFFFAOYSA-N Reserpilin Natural products COC(=O)C1COCC2CN3CCc4c([nH]c5cc(OC)c(OC)cc45)C3CC12 LCQMZZCPPSWADO-UHFFFAOYSA-N 0.000 description 1
- QEVHRUUCFGRFIF-SFWBKIHZSA-N Reserpine Natural products O=C(OC)[C@@H]1[C@H](OC)[C@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)C[C@H]2[C@@H]1C[C@H]1N(C2)CCc2c3c([nH]c12)cc(OC)cc3 QEVHRUUCFGRFIF-SFWBKIHZSA-N 0.000 description 1
- 235000004789 Rosa xanthina Nutrition 0.000 description 1
- 241000220222 Rosaceae Species 0.000 description 1
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 1
- 208000006268 Sarcoma 180 Diseases 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 208000032140 Sleepiness Diseases 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- UXRMWRBWCAGDQB-UHFFFAOYSA-N Theaflavin Natural products C1=CC(C2C(CC3=C(O)C=C(O)C=C3O2)O)=C(O)C(=O)C2=C1C(C1OC3=CC(O)=CC(O)=C3CC1O)=CC(O)=C2O UXRMWRBWCAGDQB-UHFFFAOYSA-N 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 208000012886 Vertigo Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 239000002170 aldosterone antagonist Substances 0.000 description 1
- 229940083712 aldosterone antagonist Drugs 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229940127282 angiotensin receptor antagonist Drugs 0.000 description 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000007953 anoxia Effects 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000000767 anti-ulcer Effects 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940127088 antihypertensive drug Drugs 0.000 description 1
- 239000004019 antithrombin Substances 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 229940107666 astragalus root Drugs 0.000 description 1
- 229960005370 atorvastatin Drugs 0.000 description 1
- 210000003050 axon Anatomy 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 235000001465 calcium Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 150000001746 carotenes Chemical class 0.000 description 1
- 235000005473 carotenes Nutrition 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 208000023652 chronic gastritis Diseases 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 208000000718 duodenal ulcer Diseases 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 239000000686 essence Substances 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 229960003765 fluvastatin Drugs 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 230000027119 gastric acid secretion Effects 0.000 description 1
- 229910052732 germanium Inorganic materials 0.000 description 1
- GNPVGFCGXDBREM-UHFFFAOYSA-N germanium atom Chemical compound [Ge] GNPVGFCGXDBREM-UHFFFAOYSA-N 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 210000003709 heart valve Anatomy 0.000 description 1
- 208000031169 hemorrhagic disease Diseases 0.000 description 1
- 230000010224 hepatic metabolism Effects 0.000 description 1
- 208000021760 high fever Diseases 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 208000023589 ischemic disease Diseases 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229960004844 lovastatin Drugs 0.000 description 1
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 1
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 1
- 239000003055 low molecular weight heparin Substances 0.000 description 1
- 201000003102 mental depression Diseases 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000000865 mononuclear phagocyte system Anatomy 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 208000016366 nasal cavity polyp Diseases 0.000 description 1
- 229940053128 nerve growth factor Drugs 0.000 description 1
- 210000000607 neurosecretory system Anatomy 0.000 description 1
- 206010029410 night sweats Diseases 0.000 description 1
- 230000036565 night sweats Effects 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 229940039716 prothrombin Drugs 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- BJOIZNZVOZKDIG-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C([C]5C=CC(OC)=CC5=N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 BJOIZNZVOZKDIG-MDEJGZGSSA-N 0.000 description 1
- 229960003147 reserpine Drugs 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 238000000518 rheometry Methods 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- MDMGHDFNKNZPAU-UHFFFAOYSA-N roserpine Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(OC(C)=O)C(OC)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 MDMGHDFNKNZPAU-UHFFFAOYSA-N 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 229960002855 simvastatin Drugs 0.000 description 1
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 1
- 231100000046 skin rash Toxicity 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 229960002256 spironolactone Drugs 0.000 description 1
- LXMSZDCAJNLERA-ZHYRCANASA-N spironolactone Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 235000014620 theaflavin Nutrition 0.000 description 1
- IPMYMEWFZKHGAX-ZKSIBHASSA-N theaflavin Chemical compound C1=C2C([C@H]3OC4=CC(O)=CC(O)=C4C[C@H]3O)=CC(O)=C(O)C2=C(O)C(=O)C=C1[C@@H]1[C@H](O)CC2=C(O)C=C(O)C=C2O1 IPMYMEWFZKHGAX-ZKSIBHASSA-N 0.000 description 1
- 229940026509 theaflavin Drugs 0.000 description 1
- 235000008118 thearubigins Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- RZWIIPASKMUIAC-VQTJNVASSA-N thromboxane Chemical compound CCCCCCCC[C@H]1OCCC[C@@H]1CCCCCCC RZWIIPASKMUIAC-VQTJNVASSA-N 0.000 description 1
- 230000003867 tiredness Effects 0.000 description 1
- 208000016255 tiredness Diseases 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 239000005526 vasoconstrictor agent Substances 0.000 description 1
- 231100000889 vertigo Toxicity 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 235000020990 white meat Nutrition 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L31/00—Edible extracts or preparations of fungi; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/34—Campanulaceae (Bellflower family)
- A61K36/344—Codonopsis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/734—Crataegus (hawthorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/82—Theaceae (Tea family), e.g. camellia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/15—Preparation or pretreatment of starting material involving mechanical treatment, e.g. chopping up, cutting or grinding
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/19—Preparation or pretreatment of starting material involving fermentation using yeast, bacteria or both; enzymatic treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/35—Extraction with lipophilic solvents, e.g. Hexane or petrol ether
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Botany (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Molecular Biology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开了一种用于心脑血管病膳食干预的膳食组合物及制备方法;膳食组合物中各成分的重量百分比分别为茶色素40~60%、黄芪提取物5~15%、金茶花提取物5~15%、党参提取物5~15%、猴头菇提取物5~15%、山楂提取物5~15%。其制备方法包括以下步骤:S1、制备茶色素粉末,备用;S2、制备黄芪提取物粉末,备用;S3、制备金茶花提取物粉末,备用;S4、制备党参提取物粉末,备用;S5、制备猴头菇提取物粉末,备用S6、制备山楂提取物粉末,备用;S7、将步骤将步骤S1、S2、S3、S4、S5、S6所得到粉末按重量百分比混合均匀即得膳食组合物。本发明中的膳食组合物对心脑血管疾病具有极好的预防、调理效果。
Description
技术领域
本发明涉及涉及食品领域,尤其涉及一种用于心脑血管病膳食干预的膳食组合物及制备方法。
背景技术
心脑血管疾病是心脏血管和脑血管疾病的统称,泛指由于高脂血症、血液黏稠、动脉粥样硬化、高血压等所导致的心脏、大脑及全身组织发生的缺血性或出血性疾病。心脑血管疾病是一种严重威胁人类,特别是50岁以上中老年人健康的常见病,具有高患病率、高致残率和高死亡率的特点,即使应用目前最先进、完善的治疗手段,仍可有50%以上的脑血管意外幸存者生活不能完全自理,全世界每年死于心脑血管疾病的人数高达1500万人,居各种死因首位。
防治心血管疾病,要从影响健康的因素做起,学习健康的生活方式。首先要坚持适量运动,第二是合理饮食。要做好心血管疾病的预防,应坚持使用有科学证据、有预防作用、能改善预后的药物。目前,普遍采用的措施是降血压达标,并且有了一系列有效的降压药物。降血压达标可更大幅度减少致残致死后果。普通人群血压需控制在140/90mmHg以下,合并糖尿病、冠心病、肾功能不全人群血压需控制在130/80mmHg以下。
降血压药物非常广泛,如他汀类药物(氟伐他汀、辛伐他汀、阿托伐他汀等);预防血栓的药物阿司匹林、氯比格雷、血小板糖蛋白Ⅱb、Ⅲa受体拮抗剂、低分子肝素等;拮抗神经内分泌系统的药物,如血管紧张素转换酶抑制剂(卡托普利、洛丁新)、血管紧张素受体拮抗剂(代文)、β受体阻滞剂(倍他乐克)、醛固酮拮抗剂(螺内酯),这些药物不仅可改善症状,而且可明显改善预后,降低总死亡率,因此,这些药物的广泛应用对心血管疾病的预防非常重要。
目前治疗心脑血管病的药物虽然很多,效果也很好,但是大多数还是抗生素类药物。如阿司匹林,该药品对血小板聚集有抑制作用,阻止血栓形成,临床可用于预防暂时性脑缺血发作(TIA)、心肌梗塞、心房颤动、人工心脏瓣膜、动静脉瘘或其他手术后的血栓形成。但是,不良反应也有多种表现。胃肠道反应:较常见的症状有恶心、呕吐、上腹部不适或疼痛等;过敏反应:特异性体质者服用阿司匹林后可引起皮疹、血管神经性水肿及哮喘等;过敏反应,多见于中年人或鼻炎、鼻息肉患者。
又如利血平,最大优点是显效快,药价便宜。但缺点较多,常见嗜睡,疲倦,长期应用会导致精神抑郁。利血平不良反应:鼻塞、乏力、嗜睡、腹泻,胃酸分泌过多,诱发溃疡病妊娠期增加胎儿呼吸合并症等;卡托普利不良反应:恶心、眩晕、味觉减退、皮疹,个别患者可出现尿蛋白、粒细胞缺乏症,肝功能异常等。
由此可见,这些药物使人们在用药过程中达到治疗的好处同时,同时也受到了毒副作用的健康侵害,目前尚未找到一种既疗效好,又毒副作用少的药物。
因此,研发一种集中医药学、营养学和预防医学于一体,采用天然植物现代生物技术发酵提取的无抗高效,防治兼用的配方食品,正是健康中国行动计划对重大疾病心脑血管防治的需求。
发明内容
本发明目的是针对上述问题,提供一种可以改善心脑血管病治疗效果、成本较低的用于心脑血管病膳食干预的膳食组合物及制备方法。
为了实现上述目的,本发明的技术方案是:
一种用于心脑血管病膳食干预的膳食组合物,所述膳食组合物包括茶色素、黄芪提取物、金茶花提取物、党参提取物、猴头菇提取物、山楂提取物;所述茶色素、黄芪提取物、金茶花提取物、党参提取物、猴头菇提取物、山楂提取物的重量百分比分别为茶色素40~60%、黄芪提取物5~15%、金茶花提取物5~15%、党参提取物5~15%、猴头菇提取物5~15%、山楂提取物5~15%。
进一步的,所述茶色素、黄芪提取物、金茶花提取物、党参提取物、猴头菇提取物、山楂提取物的重量百分比分别为茶色素50%、黄芪提取物10%、金茶花提取物10%、党参提取物10%、猴头菇提取物10%、山楂提取物10%。
一种膳食组合物的制备方法,包括以下步骤:
S1、制备茶色素粉末,备用;
S2、制备黄芪提取物粉末,备用;
S3、制备金茶花提取物粉末,备用;
S4、制备党参提取物粉末,备用;
S5、制备猴头菇提取物粉末,备用;
S6、制备山楂提取物粉末,备用;
S7、将步骤将步骤S1、S2、S3、S4、S5、S6所得到的茶色素粉末、黄芪提取物粉末、金茶花提取物粉末、党参提取物粉末、猴头菇提取物粉末、山楂提取物粉末按重量百分比混合均匀即得膳食组合物。
进一步的,所述步骤S1中制备茶色素粉末包括以下步骤:
S11、将绿茶茶叶粉碎到75~85目,将其放入浓度为75~85%的乙醇溶液中;绿茶茶叶与乙醇溶液的体积比为:1:100;
S12、将乙醇溶液加热到65~75℃后使用滤膜过滤,除去残渣得到茶多酚提取原液;
S13、将茶多酚提取原液进行低温真空浓缩,在65~75℃温度条件下喷雾干燥,即得茶色素粉末。
进一步的,所述步骤S2中制备黄芪提取物粉末包括以下步骤:
S21、将黄芪放置在乙醇和乙醚的混合液中进行回流脱脂,得到药渣;乙醇和乙醚的混合液中乙醇与乙醚的比例为2:1;
S22、采用沸水提取法对药渣进行提取,提取过后进行过滤、浓缩,得到黄芪浓缩液;
S23、将黄芪浓缩液在3~5℃的温度条件下放置40~50h,进行离心操作后取上清液;
S24、在上清液中加入3~5倍量的乙醇,再次进行离心操作后取沉淀物;
S25、依次使用95%乙醇、无水乙醇、丙酮和乙醚对沉淀物进行洗涤,干燥后即得黄芪提取物粉末。
进一步的,所述步骤S3中制备金茶花提取物粉末包括以下步骤:
S31、将金茶花粉碎过筛得到金茶花粉末;
S32、将金茶花粉末放入乙醇溶液中进行提取并过滤得到初次滤渣;
S33、将初次滤渣放入水中进行第一次水提取,离心后过滤得到第一次水提取滤液和二次滤渣;
S34、在二次滤渣中加入纤维素酶进行酶解,酶解后进行灭酶;
S35、将二次滤渣进行第二次水提取,离心后过滤得到第二次水提取滤液;
S36、将第一次水提取滤液与第二次水提取滤液合并蒸干,喷雾干燥后即得金茶花提取物粉末。
进一步的,所述步骤S4中制备党参提取物粉末包括以下步骤:
S41、将党参放置在乙醇和乙醚的混合液中进行回流脱脂,得到药渣;乙醇和乙醚的混合液中乙醇与乙醚的比例为2:1;
S42、采用沸水提取法对药渣进行提取,提取过后进行过滤、浓缩,得到党参浓缩液;
S43、将党参浓缩液在3~5℃的温度条件下放置40~50h,进行离心操作后取上清液;
S44、在上清液中加入3~5倍量的乙醇,再次进行离心操作后取沉淀物;
S45、依次使用95%乙醇、无水乙醇、丙酮和乙醚对沉淀物进行洗涤,干燥后即得党参提取物粉末。
进一步的,所述步骤S5中制备猴头菇提取物粉末包括以下步骤:
S51、在液体培养基中接入液体猴头菇菌丝体;
S52、将液体培养基导入一级种子罐并恒温培养;
S53、将液体培养基导入二级种子罐并恒温培养;
S54、将液体培养基导入发酵罐并恒温培养,得到猴头菇菌丝体发酵原液;
S55、将菌丝体发酵原液进行水煮,离心后取上清液;
S56、将上清液进行低温真空浓缩,得到猴头菇多糖浓缩液;
S57、对猴头菇多糖浓缩液使用乙醇醇沉,过滤后回收乙醇,喷雾干燥后即得猴头菇提取物粉末。
进一步的,所述步骤S6中制备山楂提取物粉末包括以下步骤:
S61、将山楂粉碎过筛得到山楂粉末;
S62、将山楂粉末放入乙醇溶液中进行提取并过滤得到初次滤渣;
S63、将初次滤渣放入水中进行第一次水提取,离心后过滤得到第一次水提取滤液和二次滤渣;
S64、在二次滤渣中加入纤维素酶进行酶解,酶解后进行灭酶;
S65、将二次滤渣进行第二次水提取,离心后过滤得到第二次水提取滤液;
S66、将第一次水提取滤液与第二次水提取滤液合并蒸干,喷雾干燥后即得山楂提取物粉末。
与现有技术相比,本发明具有的优点和积极效果是:
1、本发明将多种天然植物与药食同源食品的活性有效成分进行搭配,具有药食同用,优势互补的效果,同时对心脑血管病等重大疾病起到营养干预作用;
2、本发明的生产工艺全部为现代中药生物工艺,采用液态发酵菌丝体提取的真菌多糖,可以获得含量高达25%以上天然植物活性成分,这些成分虽然来自于食品,但是经过提取后可作为中药的上品,具有极好的调理效果;
3、本发明可替代抗生素使用,适合心脑血管及其相关的高血压、高血糖、高血脂和血栓的防治,并且其可以放心食用,没有任何潜在的健康危害;
4、本发明便于全面推广应用,有利于国家对心脑血管等重大疾病的防治行动,同时有利于健康中国战略的全方面实施。
具体实施方式
下面将结合本发明的实施例,对本发明实施例中的技术方案进行清楚、完整地描述,显然,所描述的实施例仅仅是本发明一部分实施例,而不是全部的实施例。基于本发明中的实施例,本领域普通技术人员在没有做出创造性劳动前提下所获得的所有其他实施例,所作的任何修改、等同替换、改进等,均应包含在本发明的保护范围之内。
本发明中的膳食组合物由茶色素、黄芪提取物、金茶花提取物、党参提取物、猴头菇提取物、山楂提取物六味植物精华组合而成,针对心脑血管病及其高血压、高血脂、高血糖、脑血栓病症,应用药食同源天然植物进行膳食营养配伍,达到活血化瘀,升阳健脾,疏通血管之目的。
实施例1、本实施例中的膳食组合物包括茶色素、黄芪提取物、金茶花提取物、党参提取物、猴头菇提取物、山楂提取物;所述茶色素、黄芪提取物、金茶花提取物、党参提取物、猴头菇提取物、山楂提取物的重量百分比分别为茶色素40%、黄芪提取物5%、金茶花提取物15%、党参提取物15%、猴头菇提取物15%、山楂提取物10%。
制备上述膳食组合物包括以下步骤:
S1、制备茶色素粉末,备用;
S11、将绿茶茶叶粉碎到75目,将其放入浓度为75%的乙醇溶液中;绿茶茶叶与乙醇溶液的体积比为:1:100;
S12、将乙醇溶液加热到65℃后使用滤膜过滤,除去残渣得到茶多酚提取原液;
S13、将茶多酚提取原液进行低温真空浓缩,在65℃温度条件下喷雾干燥,即得茶色素粉末;
S2、制备黄芪提取物粉末,备用;
S21、将黄芪放置在乙醇和乙醚的混合液中进行回流脱脂,得到药渣;乙醇和乙醚的混合液中乙醇与乙醚的比例为2:1;
S22、采用沸水提取法对药渣进行提取,提取过后进行过滤、浓缩,得到黄芪浓缩液;
S23、将黄芪浓缩液在3℃的温度条件下放置40h,进行离心操作后取上清液;
S24、在上清液中加入3倍量的乙醇,再次进行离心操作后取沉淀物;
S25、依次使用95%乙醇、无水乙醇、丙酮和乙醚对沉淀物进行洗涤,干燥后即得黄芪提取物粉末;
S3、制备金茶花提取物粉末,备用;
S31、将金茶花粉碎过筛得到金茶花粉末;
S32、将金茶花粉末放入乙醇溶液中进行提取并过滤得到初次滤渣;
S33、将初次滤渣放入水中进行第一次水提取,离心后过滤得到第一次水提取滤液和二次滤渣;
S34、在二次滤渣中加入纤维素酶进行酶解,酶解后进行灭酶;
S35、将二次滤渣进行第二次水提取,离心后过滤得到第二次水提取滤液;
S36、将第一次水提取滤液与第二次水提取滤液合并蒸干,喷雾干燥后即得金茶花提取物粉末;
S4、制备党参提取物粉末,备用;
S41、将党参放置在乙醇和乙醚的混合液中进行回流脱脂,得到药渣;乙醇和乙醚的混合液中乙醇与乙醚的比例为2:1;
S42、采用沸水提取法对药渣进行提取,提取过后进行过滤、浓缩,得到党参浓缩液;
S43、将党参浓缩液在3℃的温度条件下放置40h,进行离心操作后取上清液;
S44、在上清液中加入3~倍量的乙醇,再次进行离心操作后取沉淀物;
S45、依次使用95%乙醇、无水乙醇、丙酮和乙醚对沉淀物进行洗涤,干燥后即得党参提取物粉末;
S5、制备猴头菇提取物粉末,备用;
S51、在液体培养基中接入液体猴头菇菌丝体;
S52、将液体培养基导入一级种子罐并恒温培养;
S53、将液体培养基导入二级种子罐并恒温培养;
S54、将液体培养基导入发酵罐并恒温培养,得到猴头菇菌丝体发酵原液;
S55、将菌丝体发酵原液进行水煮,离心后取上清液;
S56、将上清液进行低温真空浓缩,得到猴头菇多糖浓缩液;
S57、对猴头菇多糖浓缩液使用乙醇醇沉,过滤后回收乙醇,喷雾干燥后即得猴头菇提取物粉末;
S6、制备山楂提取物粉末,备用;
S61、将山楂粉碎过筛得到山楂粉末;
S62、将山楂粉末放入乙醇溶液中进行提取并过滤得到初次滤渣;
S63、将初次滤渣放入水中进行第一次水提取,离心后过滤得到第一次水提取滤液和二次滤渣;
S64、在二次滤渣中加入纤维素酶进行酶解,酶解后进行灭酶;
S65、将二次滤渣进行第二次水提取,离心后过滤得到第二次水提取滤液;S66、将第一次水提取滤液与第二次水提取滤液合并蒸干,喷雾干燥后即得山楂提取物粉末。
S7、将步骤将步骤S1、S2、S3、S4、S5、S6所得到的茶色素粉末、黄芪提取物粉末、金茶花提取物粉末、党参提取物粉末、猴头菇提取物粉末、山楂提取物粉末按茶色素40%、黄芪提取物5%、金茶花提取物15%、党参提取物15%、猴头菇提取物15%、山楂提取物10%的重量百分比混合均匀即得膳食组合物。
实施例2、本实施例中的膳食组合物包括茶色素、黄芪提取物、金茶花提取物、党参提取物、猴头菇提取物、山楂提取物;所述茶色素、黄芪提取物、金茶花提取物、党参提取物、猴头菇提取物、山楂提取物的重量百分比分别为茶色素50%、黄芪提取物10%、金茶花提取物10%、党参提取物10%、猴头菇提取物10%、山楂提取物10%。
制备上述膳食组合物包括以下步骤:
S1、制备茶色素粉末,备用;
S11、将绿茶茶叶粉碎到80目,将其放入浓度为80%的乙醇溶液中;绿茶茶叶与乙醇溶液的体积比为:1:100;
S12、将乙醇溶液加热到70℃后使用滤膜过滤,除去残渣得到茶多酚提取原液;
S13、将茶多酚提取原液进行低温真空浓缩,在70℃温度条件下喷雾干燥,即得茶色素粉末;
S2、制备黄芪提取物粉末,备用;
S21、将黄芪放置在乙醇和乙醚的混合液中进行回流脱脂,得到药渣;乙醇和乙醚的混合液中乙醇与乙醚的比例为2:1;
S22、采用沸水提取法对药渣进行提取,提取过后进行过滤、浓缩,得到黄芪浓缩液;
S23、将黄芪浓缩液在4℃的温度条件下放置48h,进行离心操作后取上清液;
S24、在上清液中加入4倍量的乙醇,再次进行离心操作后取沉淀物;
S25、依次使用95%乙醇、无水乙醇、丙酮和乙醚对沉淀物进行洗涤,干燥后即得黄芪提取物粉末;
S3、制备金茶花提取物粉末,备用;
S31、将金茶花粉碎过筛得到金茶花粉末;
S32、将金茶花粉末放入乙醇溶液中进行提取并过滤得到初次滤渣;
S33、将初次滤渣放入水中进行第一次水提取,离心后过滤得到第一次水提取滤液和二次滤渣;
S34、在二次滤渣中加入纤维素酶进行酶解,酶解后进行灭酶;
S35、将二次滤渣进行第二次水提取,离心后过滤得到第二次水提取滤液;
S36、将第一次水提取滤液与第二次水提取滤液合并蒸干,喷雾干燥后即得金茶花提取物粉末;
S4、制备党参提取物粉末,备用;
S41、将党参放置在乙醇和乙醚的混合液中进行回流脱脂,得到药渣;乙醇和乙醚的混合液中乙醇与乙醚的比例为2:1;
S42、采用沸水提取法对药渣进行提取,提取过后进行过滤、浓缩,得到党参浓缩液;
S43、将党参浓缩液在4℃的温度条件下放置48h,进行离心操作后取上清液;
S44、在上清液中加入4倍量的乙醇,再次进行离心操作后取沉淀物;
S45、依次使用95%乙醇、无水乙醇、丙酮和乙醚对沉淀物进行洗涤,干燥后即得党参提取物粉末;
S5、制备猴头菇提取物粉末,备用;
S51、在液体培养基中接入液体猴头菇菌丝体;
S52、将液体培养基导入一级种子罐并恒温培养;
S53、将液体培养基导入二级种子罐并恒温培养;
S54、将液体培养基导入发酵罐并恒温培养,得到猴头菇菌丝体发酵原液;
S55、将菌丝体发酵原液进行水煮,离心后取上清液;
S56、将上清液进行低温真空浓缩,得到猴头菇多糖浓缩液;
S57、对猴头菇多糖浓缩液使用乙醇醇沉,过滤后回收乙醇,喷雾干燥后即得猴头菇提取物粉末;
S6、制备山楂提取物粉末,备用;
S61、将山楂粉碎过筛得到山楂粉末;
S62、将山楂粉末放入乙醇溶液中进行提取并过滤得到初次滤渣;
S63、将初次滤渣放入水中进行第一次水提取,离心后过滤得到第一次水提取滤液和二次滤渣;
S64、在二次滤渣中加入纤维素酶进行酶解,酶解后进行灭酶;
S65、将二次滤渣进行第二次水提取,离心后过滤得到第二次水提取滤液;S66、将第一次水提取滤液与第二次水提取滤液合并蒸干,喷雾干燥后即得山楂提取物粉末。
S7、将步骤将步骤S1、S2、S3、S4、S5、S6所得到的茶色素粉末、黄芪提取物粉末、金茶花提取物粉末、党参提取物粉末、猴头菇提取物粉末、山楂提取物粉末按茶色素50%、黄芪提取物10%、金茶花提取物10%、党参提取物10%、猴头菇提取物10%、山楂提取物10%的重量百分比混合均匀即得膳食组合物。
实施例3、本实施例中的膳食组合物包括茶色素、黄芪提取物、金茶花提取物、党参提取物、猴头菇提取物、山楂提取物;所述茶色素、黄芪提取物、金茶花提取物、党参提取物、猴头菇提取物、山楂提取物的重量百分比分别为茶色素60%、黄芪提取物15%、金茶花提取物5%、党参提取物10%、猴头菇提取物5%、山楂提取物5%。
制备上述膳食组合物包括以下步骤:
S1、制备茶色素粉末,备用;
S11、将绿茶茶叶粉碎到85目,将其放入浓度为85%的乙醇溶液中;绿茶茶叶与乙醇溶液的体积比为:1:100;
S12、将乙醇溶液加热到75℃后使用滤膜过滤,除去残渣得到茶多酚提取原液;
S13、将茶多酚提取原液进行低温真空浓缩,在75℃温度条件下喷雾干燥,即得茶色素粉末;
S2、制备黄芪提取物粉末,备用;
S21、将黄芪放置在乙醇和乙醚的混合液中进行回流脱脂,得到药渣;乙醇和乙醚的混合液中乙醇与乙醚的比例为2:1;
S22、采用沸水提取法对药渣进行提取,提取过后进行过滤、浓缩,得到黄芪浓缩液;
S23、将黄芪浓缩液在5℃的温度条件下放置50h,进行离心操作后取上清液;
S24、在上清液中加入5倍量的乙醇,再次进行离心操作后取沉淀物;
S25、依次使用95%乙醇、无水乙醇、丙酮和乙醚对沉淀物进行洗涤,干燥后即得黄芪提取物粉末;
S3、制备金茶花提取物粉末,备用;
S31、将金茶花粉碎过筛得到金茶花粉末;
S32、将金茶花粉末放入乙醇溶液中进行提取并过滤得到初次滤渣;
S33、将初次滤渣放入水中进行第一次水提取,离心后过滤得到第一次水提取滤液和二次滤渣;
S34、在二次滤渣中加入纤维素酶进行酶解,酶解后进行灭酶;
S35、将二次滤渣进行第二次水提取,离心后过滤得到第二次水提取滤液;
S36、将第一次水提取滤液与第二次水提取滤液合并蒸干,喷雾干燥后即得金茶花提取物粉末;
S4、制备党参提取物粉末,备用;
S41、将党参放置在乙醇和乙醚的混合液中进行回流脱脂,得到药渣;乙醇和乙醚的混合液中乙醇与乙醚的比例为2:1;
S42、采用沸水提取法对药渣进行提取,提取过后进行过滤、浓缩,得到党参浓缩液;
S43、将党参浓缩液在5℃的温度条件下放置50h,进行离心操作后取上清液;
S44、在上清液中加入5倍量的乙醇,再次进行离心操作后取沉淀物;
S45、依次使用95%乙醇、无水乙醇、丙酮和乙醚对沉淀物进行洗涤,干燥后即得党参提取物粉末;
S5、制备猴头菇提取物粉末,备用;
S51、在液体培养基中接入液体猴头菇菌丝体;
S52、将液体培养基导入一级种子罐并恒温培养;
S53、将液体培养基导入二级种子罐并恒温培养;
S54、将液体培养基导入发酵罐并恒温培养,得到猴头菇菌丝体发酵原液;
S55、将菌丝体发酵原液进行水煮,离心后取上清液;
S56、将上清液进行低温真空浓缩,得到猴头菇多糖浓缩液;
S57、对猴头菇多糖浓缩液使用乙醇醇沉,过滤后回收乙醇,喷雾干燥后即得猴头菇提取物粉末;
S6、制备山楂提取物粉末,备用;
S61、将山楂粉碎过筛得到山楂粉末;
S62、将山楂粉末放入乙醇溶液中进行提取并过滤得到初次滤渣;
S63、将初次滤渣放入水中进行第一次水提取,离心后过滤得到第一次水提取滤液和二次滤渣;
S64、在二次滤渣中加入纤维素酶进行酶解,酶解后进行灭酶;
S65、将二次滤渣进行第二次水提取,离心后过滤得到第二次水提取滤液;S66、将第一次水提取滤液与第二次水提取滤液合并蒸干,喷雾干燥后即得山楂提取物粉末。
S7、将步骤将步骤S1、S2、S3、S4、S5、S6所得到的茶色素粉末、黄芪提取物粉末、金茶花提取物粉末、党参提取物粉末、猴头菇提取物粉末、山楂提取物粉末按茶色素60%、黄芪提取物15%、金茶花提取物5%、党参提取物10%、猴头菇提取物5%、山楂提取物5%的重量百分比混合均匀即得膳食组合物。
下面对各组成成分的食用效果进行介绍;
茶色素;主攻方向:解毒,抗凝,降粘,溶栓,活血、增强免疫。
茶色素是茶叶中的水溶性有色物质的总称,有多种组分。根据颜色可分为茶黄素、茶红素、茶褐素3类。现已发现,茶色素具有调节血脂、抗氧化、抗肿瘤、抗心脑血管疾病的多种药理活性,以及调节机体免疫、抗菌、抗病毒等多方面的药理作用。
根据江西师范大学生命科学学院对茶色素药理作用研究表明:在高脂血症大鼠动物模型中,茶色素能显著降低动物血清中三酰甘油(TG)、总胆固醇(TC)、低密度脂蛋白胆固醇(LDL—C)含量,同时能显著升高高密度脂蛋白胆固醇(HDL-C)含量,并能减少动脉脂质斑块形成;在心脑血管疾病的药理作用方面,口服茶叶提取的茶色素能减少心脑血管疾病的危险因子。
近年来的研究表明,血管内皮素的自动平衡和失调对心脑血管疾病的病理状态和临床表现起到重要作用。茶色素可显著降低血浆内皮素水平,增加尿中内皮素的排泄量,并认为茶色素是对多种心血管疾病和其他相关疾病产生治疗作用的基础之一。茶色素对微循环有明显的改善作用,具有降低血栓素等缩血管物质含量,延长血液凝固时间、凝血酶原时间、抗凝血酶作用时间,降低纤维蛋白原含量,减少血小板粘附与聚集等效果,并对已经凝固的血小板有解聚合作用,对多种心脑血管疾病发挥独特的治疗作用。
针对茶色素治疗高血脂症的疗效观察及对血液流变学、血栓指标的影响,安徽省泰和县心脑血管病防治研究所进行研究:应用茶色素治疗高脂血症病人68例,目的在于观察茶色素对高脂血症的临床疗效及对血液流变学、血栓指标的影响。其方法为:所有观察对象服用茶色素,每次两粒,每日三次,连续服用一个月。治疗前后均空腹查血脂、血糖、肝肾功能、血液流变学及血拴指标作比较。结果表明:降低胆固醇总有效率为66.1%;降低甘油三酯总有效率达73.5%。茶色素不但有良好的降脂降粘及抗凝作用,而且具有抑制血小板聚集及降低血纤维蛋白原的功能,可用于心脑血管儿病的预防及治疗。
黄芪、金茶花提取物;作用机理:辅助茶色素补气升阳,解热镇痛,抗菌消炎,疏通血管,抑制脂肪积累。
黄芪,性甘,微温,具有补气升阳,固表止汗,利尿消肿,生津养血,行滞通痹,脱毒排脓,敛疮生肌药理作用。适用于自汗、盗汗、浮肿、内伤劳倦、脾虚、泄泻、脱肛及一切气衰血虚之症,有利于高血栓和心脑血管气血调理,但有高热、大渴、便秘等实热症者忌用。
金花茶,属于山茶科、山茶属,与茶、山茶、南山茶、油茶、茶梅等为孪生姐妹,是国家一级保护植物之一。该稀有物种含有天然有机锗、锌、硒、矾等多种对人体有重要保健作用的微量元素,以及茶多酚、黄酮类人体必需的氨基酸、维生素等。金花茶在有效降低血糖、血压的同时,可有效降低血脂,改善因高血压而引起的各种不适应症状,降低血清中胆固醇和B-脂蛋白,促进胰岛素分泌、增强免疫力、调节血流量,具有防止动脉粥样硬化,抗菌消炎、清热解毒、通便利尿去湿,增进肝脏代谢等作用。
大连理工大学硕士在金花茶的花提取物降血脂作用研究中,以脂血症小鼠和HepG2细胞为研究对象,分别研究金花茶提取物对体内高脂血症小鼠的降血脂影响以及对油酸诱导HepG2细胞脂肪积累的影响。结果表明金花茶提取物能够明显改善高脂血症小鼠毛发竖立、发黄、油腻的状态;金花茶提取物能够明显降低小鼠血清中TC、TG、LDL.C水平,升高HDL.C水平。
党参提取物;作用机理:调节内热消渴,补中益气,健脾益肺。
党参为桔梗科植物素花党参或川党参的干燥根,具有补中益气丸,健脾益肺之功效,同时具有扩张周围血管而降低血压,抑制肾上腺素的升压作用;主治脾肺虚弱、气短心悸、食少便溏、虚喘咳嗽、内热消渴等症状。党参可以增强网状内皮系统功能;增强骨髓的造血功能;党参多糖同其它药用植物一样,具有广泛的药理作用,主要包括调节机体免疫,清除自由基和造血功能。
猴头菇、山楂提取物;作用机理:保肝护胃,增加心肌收缩力,改善血流循环。
猴头菇又名猴头菌、花菜菌、对口菇等多个名字,隶属于担子菌亚门、层菌纲、猴头菌目、猴头菌科、猴头菌属。自古以来猴头菇就是有名的山珍,其肉质洁白、柔软细嫩、清香可口,营养丰富,是我国著名的八大“山珍”之一。
猴头菇的主要成分是多糖类和猴头菌素。猴头菇多糖对小白鼠肉瘤180和艾氏腹水癌有明显的抑制作用,同时具有助消化、利五脏的功能,对慢性胃炎、十二指肠溃疡等多种消化道疾病均有较好的疗效,能提高人体免疫能力。猴头菌素是猴头菇另一类活性成份。它可促使神经生长因子(NGF:可延长N轴突,维持N细胞生存,调节神经细胞的产生并对衰老动物神经细胞的再生发挥作用)的合成,其活性大大强于肾上腺素,其主要成分为猴头菇菌素A.B.C.E.F,化学成份为萜类物质。
猴头菌素具有抗溃疡、抗炎、抗肿瘤、保肝护肝,提高机体耐缺氧能力,增加心脏血液输出量,加速机体血液循环,降低血糖和血脂的作用。
山楂为蔷薇科植物山楂的干燥成熟果实。山楂提取物主要成分是黄酮类物质、三萜类物质、有机酸、糖类、蛋白质、脂肪、维生素C、胡萝卜素、钙和铁等物质等,具有降血脂、降血压、强心和抗心律不齐等作用。山楂提取物中的三萜类物质,有强心、增加冠脉血流、改善血流循环等重要作用。
膳食组合物中以茶色素为主体的膳食配伍原料,全部来自国家批准生产的药食同源食品和新资源食品,按规定使用量食用,没有任何潜在的健康危害,可以替代抗生素使用,并且可用于中医养生保健和重大疾病的营养干预中;另一方面,膳食配伍的原料不用传统的粉碎和熬制方法,全部采用现代中药发酵提取技术,降解了原料中的有害物质,高效获取中药的活性成分,有效成分含量高,并且通过君臣佐使中医配伍而成,对心脑血管疾病具有极好的预防、调理效果。
Claims (9)
1.一种用于心脑血管病膳食干预的膳食组合物,其特征在于:所述膳食组合物包括茶色素、黄芪提取物、金茶花提取物、党参提取物、猴头菇提取物、山楂提取物;所述茶色素、黄芪提取物、金茶花提取物、党参提取物、猴头菇提取物、山楂提取物的重量百分比分别为茶色素40~60%、黄芪提取物5~15%、金茶花提取物5~15%、党参提取物5~15%、猴头菇提取物5~15%、山楂提取物5~15%。
2.如权利要求1所述的用于心脑血管病膳食干预的膳食组合物,其特征在于:所述茶色素、黄芪提取物、金茶花提取物、党参提取物、猴头菇提取物、山楂提取物的重量百分比分别为茶色素50%、黄芪提取物10%、金茶花提取物10%、党参提取物10%、猴头菇提取物10%、山楂提取物10%。
3.一种膳食组合物的制备方法,所述膳食组合物为权利要求1所述的用于心脑血管病膳食干预的膳食组合物,其特征在于:包括以下步骤:
S1、制备茶色素粉末,备用;
S2、制备黄芪提取物粉末,备用;
S3、制备金茶花提取物粉末,备用;
S4、制备党参提取物粉末,备用;
S5、制备猴头菇提取物粉末,备用;
S6、制备山楂提取物粉末,备用;
S7、将步骤将步骤S1、S2、S3、S4、S5、S6所得到的茶色素粉末、黄芪提取物粉末、金茶花提取物粉末、党参提取物粉末、猴头菇提取物粉末、山楂提取物粉末按重量百分比混合均匀即得膳食组合物。
4.如权利要求3所述的膳食组合物的制备方法,其特征在于:所述步骤S1中制备茶色素粉末包括以下步骤:
S11、将绿茶茶叶粉碎到75~85目,将其放入浓度为75~85%的乙醇溶液中;绿茶茶叶与乙醇溶液的体积比为:1:100;
S12、将乙醇溶液加热到65~75℃后使用滤膜过滤,除去残渣得到茶多酚提取原液;
S13、将茶多酚提取原液进行低温真空浓缩,在65~75℃温度条件下喷雾干燥,即得茶色素粉末。
5.如权利要求4所述的膳食组合物的制备方法,其特征在于:所述步骤S2中制备黄芪提取物粉末包括以下步骤:
S21、将黄芪放置在乙醇和乙醚的混合液中进行回流脱脂,得到药渣;乙醇和乙醚的混合液中乙醇与乙醚的比例为2:1;
S22、采用沸水提取法对药渣进行提取,提取过后进行过滤、浓缩,得到黄芪浓缩液;
S23、将黄芪浓缩液在3~5℃的温度条件下放置40~50h,进行离心操作后取上清液;
S24、在上清液中加入3~5倍量的乙醇,再次进行离心操作后取沉淀物;
S25、依次使用95%乙醇、无水乙醇、丙酮和乙醚对沉淀物进行洗涤,干燥后即得黄芪提取物粉末。
6.如权利要求5所述的膳食组合物的制备方法,其特征在于:所述步骤S3中制备金茶花提取物粉末包括以下步骤:
S31、将金茶花粉碎过筛得到金茶花粉末;
S32、将金茶花粉末放入乙醇溶液中进行提取并过滤得到初次滤渣;
S33、将初次滤渣放入水中进行第一次水提取,离心后过滤得到第一次水提取滤液和二次滤渣;
S34、在二次滤渣中加入纤维素酶进行酶解,酶解后进行灭酶;
S35、将二次滤渣进行第二次水提取,离心后过滤得到第二次水提取滤液;
S36、将第一次水提取滤液与第二次水提取滤液合并蒸干,喷雾干燥后即得金茶花提取物粉末。
7.如权利要求6所述的膳食组合物的制备方法,其特征在于:所述步骤S4中制备党参提取物粉末包括以下步骤:
S41、将党参放置在乙醇和乙醚的混合液中进行回流脱脂,得到药渣;乙醇和乙醚的混合液中乙醇与乙醚的比例为2:1;
S42、采用沸水提取法对药渣进行提取,提取过后进行过滤、浓缩,得到党参浓缩液;
S43、将党参浓缩液在3~5℃的温度条件下放置40~50h,进行离心操作后取上清液;
S44、在上清液中加入3~5倍量的乙醇,再次进行离心操作后取沉淀物;
S45、依次使用95%乙醇、无水乙醇、丙酮和乙醚对沉淀物进行洗涤,干燥后即得党参提取物粉末。
8.如权利要求7所述的膳食组合物的制备方法,其特征在于:所述步骤S5中制备猴头菇提取物粉末包括以下步骤:
S51、在液体培养基中接入液体猴头菇菌丝体;
S52、将液体培养基导入一级种子罐并恒温培养;
S53、将液体培养基导入二级种子罐并恒温培养;
S54、将液体培养基导入发酵罐并恒温培养,得到猴头菇菌丝体发酵原液;
S55、将菌丝体发酵原液进行水煮,离心后取上清液;
S56、将上清液进行低温真空浓缩,得到猴头菇多糖浓缩液;
S57、对猴头菇多糖浓缩液使用乙醇醇沉,过滤后回收乙醇,喷雾干燥后即得猴头菇提取物粉末。
9.如权利要求8所述的膳食组合物的制备方法,其特征在于:所述步骤S6中制备山楂提取物粉末包括以下步骤:
S61、将山楂粉碎过筛得到山楂粉末;
S62、将山楂粉末放入乙醇溶液中进行提取并过滤得到初次滤渣;
S63、将初次滤渣放入水中进行第一次水提取,离心后过滤得到第一次水提取滤液和二次滤渣;
S64、在二次滤渣中加入纤维素酶进行酶解,酶解后进行灭酶;
S65、将二次滤渣进行第二次水提取,离心后过滤得到第二次水提取滤液;
S66、将第一次水提取滤液与第二次水提取滤液合并蒸干,喷雾干燥后即得山楂提取物粉末。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201911354632.7A CN111000237A (zh) | 2019-12-25 | 2019-12-25 | 一种用于心脑血管病膳食干预的膳食组合物及制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201911354632.7A CN111000237A (zh) | 2019-12-25 | 2019-12-25 | 一种用于心脑血管病膳食干预的膳食组合物及制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN111000237A true CN111000237A (zh) | 2020-04-14 |
Family
ID=70118052
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201911354632.7A Pending CN111000237A (zh) | 2019-12-25 | 2019-12-25 | 一种用于心脑血管病膳食干预的膳食组合物及制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111000237A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112401101A (zh) * | 2020-11-27 | 2021-02-26 | 安徽省农业科学院蚕桑研究所 | 一种沙棘蛹虫草固体饮料及其制作方法 |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001093886A1 (en) * | 2000-06-08 | 2001-12-13 | Nashai Biotech, Llc | Method of obtaining a tea pigment from tea leaves |
CN101085071A (zh) * | 2006-06-08 | 2007-12-12 | 天津天士力制药股份有限公司 | 含有丹参、山楂的中药组合物及其制剂 |
CN101347556A (zh) * | 2008-09-09 | 2009-01-21 | 毛晓敏 | 一种有益于心脑血管的组合物 |
CN104231110A (zh) * | 2014-10-21 | 2014-12-24 | 哈尔滨艾博雅食品科技开发有限公司 | 一种猴头菇粗多糖的提取方法 |
CN104274607A (zh) * | 2013-07-01 | 2015-01-14 | 上海丹康实业有限公司 | 一种中药降脂复方制剂及其制备方法 |
CN104799270A (zh) * | 2014-01-26 | 2015-07-29 | 天津中瑞药业股份有限公司 | 一种含黄芪及肌醇烟酸酯营养强化剂胶囊 |
CN106032442A (zh) * | 2015-03-16 | 2016-10-19 | 杨旭 | 一种防治心血管疾病的茶色素的提取方法 |
CN108244620A (zh) * | 2018-04-18 | 2018-07-06 | 中国农业科学院特产研究所 | 一种猴头菇养胃颗粒及其制备方法 |
-
2019
- 2019-12-25 CN CN201911354632.7A patent/CN111000237A/zh active Pending
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001093886A1 (en) * | 2000-06-08 | 2001-12-13 | Nashai Biotech, Llc | Method of obtaining a tea pigment from tea leaves |
CN101085071A (zh) * | 2006-06-08 | 2007-12-12 | 天津天士力制药股份有限公司 | 含有丹参、山楂的中药组合物及其制剂 |
CN101347556A (zh) * | 2008-09-09 | 2009-01-21 | 毛晓敏 | 一种有益于心脑血管的组合物 |
CN104274607A (zh) * | 2013-07-01 | 2015-01-14 | 上海丹康实业有限公司 | 一种中药降脂复方制剂及其制备方法 |
CN104799270A (zh) * | 2014-01-26 | 2015-07-29 | 天津中瑞药业股份有限公司 | 一种含黄芪及肌醇烟酸酯营养强化剂胶囊 |
CN104231110A (zh) * | 2014-10-21 | 2014-12-24 | 哈尔滨艾博雅食品科技开发有限公司 | 一种猴头菇粗多糖的提取方法 |
CN106032442A (zh) * | 2015-03-16 | 2016-10-19 | 杨旭 | 一种防治心血管疾病的茶色素的提取方法 |
CN108244620A (zh) * | 2018-04-18 | 2018-07-06 | 中国农业科学院特产研究所 | 一种猴头菇养胃颗粒及其制备方法 |
Non-Patent Citations (2)
Title |
---|
高颖等: "不同培养基对猴头菇菌丝体生长量及多糖含量的影响", 《辽宁科技学院学报》 * |
黄永林等: "不同溶剂提取及初步纯化的金花茶叶提取物降血脂功能实验研究", 《时珍国医国药》 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112401101A (zh) * | 2020-11-27 | 2021-02-26 | 安徽省农业科学院蚕桑研究所 | 一种沙棘蛹虫草固体饮料及其制作方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102048905B (zh) | 一种补气养血美颜口服液及其制备工艺 | |
KR20020003165A (ko) | 건강보조 발효식품의 제조방법 | |
WO2017201877A1 (zh) | 一种红曲葡萄酒及其制备方法 | |
CN104784473A (zh) | 地龙蛋白保健品 | |
CN105995712A (zh) | 一种复方滇橄榄粉及其制备方法 | |
CN103602551A (zh) | 一种有助于消食健胃复方中草药发酵保健酒及其生产方法 | |
CN104758806A (zh) | 一种治疗冠心病的煎膏剂及其制备方法 | |
KR20130104692A (ko) | 산사육 추출물을 함유하는 비만치료 및 예방용 조성물 | |
CN109125639A (zh) | 治疗痛风的中药组合物 | |
CN103549437B (zh) | 一种降压降脂保健食品及其制备方法 | |
KR20070097234A (ko) | 식용가능한 한약재를 이용한 유산발효조성물 및 그제조방법 | |
CN111000237A (zh) | 一种用于心脑血管病膳食干预的膳食组合物及制备方法 | |
CN103642627A (zh) | 一种甘草五味子山药山楂枸杞复合发酵中草药保健酒 | |
CN1105594A (zh) | 降癌灵丹 | |
CN102669340B (zh) | 一种改善营养性贫血的食品养血茶冲剂 | |
CN109527577A (zh) | 一种具有解酒护肝功能的组合物 | |
CN105012873A (zh) | 一种降血脂的月见草保健口服液及其制备方法 | |
CN101889687A (zh) | 一种富硒白花丹参茶及其制备方法 | |
CN113652461A (zh) | 一种黄精植物甾醇多糖蛋白的制备方法及其活性制品 | |
CN103340919A (zh) | 一种灵芝精粉复方软胶囊及其制备方法 | |
CN114177261A (zh) | 一种防治慢性病及抗癌保健的中草药配方 | |
CN105561179A (zh) | 防治三高血症的冲剂利脉饮及其制备方法 | |
CN109674052A (zh) | 一种沙棘六味膏及其制备方法 | |
KR20200140166A (ko) | 옻이 함유된 잡화꿀 건강보조식품 및 이의 제조방법 | |
CN103585456A (zh) | 一种海参咀嚼片 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200414 |
|
RJ01 | Rejection of invention patent application after publication |